+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Market Spotlight: Chemotherapy-Induced Anemia

  • Report

  • 32 Pages
  • February 2021
  • Region: Global
  • Citeline
  • ID: 4846160
This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The prevalence proportions of CIA and the severity of anemia vary by region, cancer type, and stage.
  • All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.
  • There are only two industry-sponsored drugs in active clinical development for CIA, both of which are in Phase III. Therapies in development for CIA focus on targets such as iron and hypoxia-inducible factor-prolyl hydroxylase. These drugs are administered via the intravenous and oral routes.
  • The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 22.5%, and the average probability a drug advances from Phase III is 82.5%. Drugs, on average, take 10.1 years from Phase I to approval, compared to 9.2 years in the overall hematology space.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III–IV, and 39% in Phase I–II.
  • Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 66 trials.
  • Amgen leads industry sponsors with the highest overall number of clinical trials for CIA, followed by Johnson & Johnson.

Table of Contents

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT
  • Iron supplements
  • Blood transfusion
  • Erythropoietin-stimulating agents (ESAs)

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
  • Roxadustat for CIA (December 9, 2019)

PROBABILITY OF SUCCESSREVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY
  • Prescription information

APPENDIX
LIST OF FIGURES
Figure 1: Overview of pipeline drugs for CIA in the US
Figure 2: Pipeline drugs for CIA, by company
Figure 3: Pipeline drugs for CIA, by drug type
Figure 4: Pipeline drugs for CIA, by classification
Figure 5: Roxadustat for CIA (December 9, 2019): Phase III - MDS (US)
Figure 6: Probability of success in the marrow or peripheral blood stimulator pipeline
Figure 7: Clinical trials in CIA
Figure 8: Top 10 drugs for clinical trials in CIA
Figure 9: Top 10 companies for clinical trials in CIA
Figure 10: CIA trials status
Figure 11: CIA trials sponsors, by phase
LIST OF TABLES
Table 1: Chemotherapy-treated patients with CIA, by grade, in the US
Table 2: Marketed drugs for CIA
Table 3: Pipeline drugs for CIA in the US
Table 4: Roxadustat for CIA (December 9, 2019)
Table 5: Historical global sales, by drug ($m), 2015–19
Table 6: Forecasted global sales, by drug ($m), 2021–25